GlassScriptPhysician profile
Jodi L Rubin
NPI 1255473872
$29,505.58
in general payments reported to CMS, 2019-2025
28 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $4,281 · 2021: $15K · 2022: $2,894 · 2023: $1,795 · 2024: $2,479 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,383.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,693.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $7,003.58 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,552.53 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $1,495.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,091.79 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $972.37 | 2019-2025 | Hizentra |
| Aerin Medical INC. | $687.47 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $687.44 | 2020-2025 | Cuvitru, Hyqvia |
| Inspire Medical Systems, INC. | $588.49 | 2021-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $382.98 | 2019-2025 | |
| Genentech USA, INC. | $379.52 | 2019-2025 | Xolair |
| Amgen INC. | $242.49 | 2022-2025 | Tezspire |
| Kaleo, INC. | $112.38 | 2021-2023 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Merck Sharp & Dohme LLC | $68.53 | 2021-2025 | Keytruda, Keytruda Qlex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $61.69 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $58.51 | 2024 | Ryaltris |
| Shire North American Group INC | $57.74 | 2019 | |
| Intersect Ent, INC. | $38.17 | 2020-2021 | |
| Medtronic, INC. | $38.00 | 2025 | Nuvent |
| Smith+Nephew, INC. | $37.93 | 2019-2022 | |
| Leo Pharma INC. | $37.07 | 2022-2023 | Adbry |
| Jubilant Hollisterstier LLC | $36.07 | 2025 | |
| Arcutis Biotherapeutics, INC. | $19.29 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $18.65 | 2019 | |
| Stryker Corporation | $17.36 | 2024 | Xpress Loprofile |
| Aimmune Therapeutics, INC. | $13.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.